0001493152-26-050479.txt : 20261106 0001493152-26-050479.hdr.sgml : 20261106 20261106163020 ACCESSION NUMBER: 0001493152-26-050479 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20261106 DATE AS OF CHANGE: 20261106 EFFECTIVENESS DATE: 20261106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vimy Pharmaceuticals Inc. CENTRAL INDEX KEY: 0002159983 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-603996 FILM NUMBER: 261532462 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 2 BLOOR STREET WEST, SUITE 2002 CITY: TORONTO PROVINCE COUNTRY: A6 ZIP: M4W1J5 BUSINESS PHONE: 4162544774 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 2 BLOOR STREET WEST, SUITE 2002 CITY: TORONTO PROVINCE COUNTRY: A6 ZIP: M4W1J5 D 1 primary_doc.xml X0708 D LIVE 0002159983 Vimy Pharmaceuticals Inc. 2 BLOOR STREET WEST SUITE 2002 TORONTO A6 ONTARIO, CANADA M4W1J5 416-254-4774 ONTARIO, CANADA None None Corporation true 2024 David John Suchon 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Executive Officer Director Chief Executive Officer Farris Smith 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Executive Officer Director President and Chair Darryl Firsten 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Director Riccardo Trecroce 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Director Christopher Burkett 2 Bloor Street West Suite 2002 Toronto A6 ONTARIO, CANADA M4W1J5 Director Pharmaceuticals Decline to Disclose 06b false 2026-10-22 false true true The Issuer sold subscription receipts, which will be converted into shares of the Issuer without consideration upon the closing of the transaction. 0 Beacon Securities US Limited 000306613 Beacon Securities Limited None 66 Wellington Street West Suite 4050 Toronto A6 ONTARIO, CANADA M5K1H1 true 278174 278174 0 The total offering amount was $390,000 in Canadian dollars. The U.S. dollar value above is based on the Federal Reserve exchange rate on October 22, 2026, of $1.4020 CAD per USD. false 2 10237 true 0 Consists of an $8,345 cash fee and 3,900 stock options, each representing 3% of subscription receipts sold in the offering; total option value estimated at $1,892 using good faith Black-Scholes valuation on 11/6/26. CAD converted to USD at the rate above. 0 false Vimy Pharmaceuticals Inc. /s/ David Suchon David Suchon Chief Executive Officer 2026-11-06